Hepion Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
November 6, 2023 |
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: | Hepion Pharmaceuticals, Inc. |
Form S-1 Registration Statement | |
Filed October 31, 2023 | |
File No. 333-275231 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Wednesday, November 8, 2023, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
HEPION PHARMACEUTICALS, INC. | ||
By: | /s/ Robert Foster | |
Name: | Robert Foster | |
Title: | Chief Executive Officer |
-1-